Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme
CuraTeQ Biologics is on track for filing a second oncology biosimilar
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The transactions resulted in a net cash inflow of Rs 183 crores for HCG in addition to the take-over of the labs and clinical research business
The foundation has been working closely with the Kidwai Memorial Institute of Oncology on several projects since 2001
The partnership is a significant step in delivering advanced cancer therapies to patients.
The state-of-the-art facility is a 350-bedded, multi-specialty tertiary care hospital
More than five drug candidates from his team progressed to human trials including drugs like Rilematovir (Phase IIb), and Bedaquiline
Updated results from the EMBER-3 study showed that the drug -- Inluriyo (imlunestrant) -- as a standalone treatment cut the risk of progression or death by 38%
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
Subscribe To Our Newsletter & Stay Updated
